1. Home
  2. SKYE vs HCVI Comparison

SKYE vs HCVI Comparison

Compare SKYE & HCVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • HCVI
  • Stock Information
  • Founded
  • SKYE 2012
  • HCVI 2021
  • Country
  • SKYE United States
  • HCVI United States
  • Employees
  • SKYE N/A
  • HCVI N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • HCVI Blank Checks
  • Sector
  • SKYE Health Care
  • HCVI Finance
  • Exchange
  • SKYE Nasdaq
  • HCVI Nasdaq
  • Market Cap
  • SKYE 172.9M
  • HCVI 176.6M
  • IPO Year
  • SKYE N/A
  • HCVI 2021
  • Fundamental
  • Price
  • SKYE $5.31
  • HCVI $10.68
  • Analyst Decision
  • SKYE Strong Buy
  • HCVI
  • Analyst Count
  • SKYE 5
  • HCVI 0
  • Target Price
  • SKYE $18.40
  • HCVI N/A
  • AVG Volume (30 Days)
  • SKYE 146.6K
  • HCVI 52.6K
  • Earning Date
  • SKYE 11-09-2024
  • HCVI 01-01-0001
  • Dividend Yield
  • SKYE N/A
  • HCVI N/A
  • EPS Growth
  • SKYE N/A
  • HCVI N/A
  • EPS
  • SKYE N/A
  • HCVI N/A
  • Revenue
  • SKYE N/A
  • HCVI N/A
  • Revenue This Year
  • SKYE N/A
  • HCVI N/A
  • Revenue Next Year
  • SKYE N/A
  • HCVI N/A
  • P/E Ratio
  • SKYE N/A
  • HCVI N/A
  • Revenue Growth
  • SKYE N/A
  • HCVI N/A
  • 52 Week Low
  • SKYE $1.44
  • HCVI $10.30
  • 52 Week High
  • SKYE $19.41
  • HCVI $11.47
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 42.98
  • HCVI 63.86
  • Support Level
  • SKYE $5.71
  • HCVI $10.62
  • Resistance Level
  • SKYE $7.11
  • HCVI $10.66
  • Average True Range (ATR)
  • SKYE 0.58
  • HCVI 0.01
  • MACD
  • SKYE -0.05
  • HCVI 0.00
  • Stochastic Oscillator
  • SKYE 0.55
  • HCVI 100.00

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About HCVI Hennessy Capital Investment Corp. VI

Hennessy Capital Investment Corp VI is a shell company.

Share on Social Networks: